When prostate cancers progress following androgen depletion therapy, there are currently
few treatment options with only one, docetaxel, that has been shown to prolong life. Recent
work has shown that castration-resistant prostate cancers (CRPCs) continue to depend on
androgen receptor (AR) signaling which is reactivated despite low serum androgen levels.
Currently available AR-targeted therapy, including GnRH agonists and antiandrogens,
cannot completely shut down AR signaling. Several mechanisms that enhance AR signaling …